We report the results of a binational, multicenter, prospective study to assess cutaneous involvement during the course of coronavirus disease 2019 (COVID-19). Between January 1 and March 15, 2020, we investigated the epidemiologic and clinical features of cutaneous manifestations in adult patients with COVID-19. The data were collected prospectively by experienced dermatologists in Wuhan, Hubei province, China, and Lecco, Lombardia region, Italy. Institutional Review Boards approved the study. Four participating hospitals (3 in China, 1 in Italy) enrolled patients diagnosed with COVID-19, according to World Health Organization interim guidance.1 Whenever possible, all new cutaneous findings and pre-existing dermatologic diagnoses were recorded at admission to assess the possible influence of hospital-based treatment and external factors. History and physical examinations were used to categorize all dermatologic conditions as pre-existing vs newly arising. This observational cross-sectional study enrolled 678 patients with polymerase chain reaction-confirmed COVID-19. Patients were classified by disease severity based on Chinese Diagnosis and Treatment Scheme for SARS-CoV-2: 6.0% (41 patients) were considered “critically-ill,” 17.5% (118 patients) “severe,” 18.7% (127 patients) “common,” and 57.8% (392 patients) “mild.” In this cohort, 53 patients (7.8%) had new dermatologic conditions that were detected at admission or during hospitalization. This subgroup was a mean age of 55.9 years (range, 28-69 years), and 60% were men (Table I ). Of the dermatologic conditions, 44% were present on the day of the COVID-19 diagnosis, roughly at the onset of the typical flu-like symptoms. The remaining 56% of dermatoses were observed at a mean of 11.7 days (range, 2-23 days after hospitalization).
De Giorgi V., Recalcati S., Jia Z., Chong W., Ding R., Deng Y., et al. (2020). Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 83(2), 674-675 [10.1016/j.jaad.2020.05.073].
Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy
Venturi F.;
2020
Abstract
We report the results of a binational, multicenter, prospective study to assess cutaneous involvement during the course of coronavirus disease 2019 (COVID-19). Between January 1 and March 15, 2020, we investigated the epidemiologic and clinical features of cutaneous manifestations in adult patients with COVID-19. The data were collected prospectively by experienced dermatologists in Wuhan, Hubei province, China, and Lecco, Lombardia region, Italy. Institutional Review Boards approved the study. Four participating hospitals (3 in China, 1 in Italy) enrolled patients diagnosed with COVID-19, according to World Health Organization interim guidance.1 Whenever possible, all new cutaneous findings and pre-existing dermatologic diagnoses were recorded at admission to assess the possible influence of hospital-based treatment and external factors. History and physical examinations were used to categorize all dermatologic conditions as pre-existing vs newly arising. This observational cross-sectional study enrolled 678 patients with polymerase chain reaction-confirmed COVID-19. Patients were classified by disease severity based on Chinese Diagnosis and Treatment Scheme for SARS-CoV-2: 6.0% (41 patients) were considered “critically-ill,” 17.5% (118 patients) “severe,” 18.7% (127 patients) “common,” and 57.8% (392 patients) “mild.” In this cohort, 53 patients (7.8%) had new dermatologic conditions that were detected at admission or during hospitalization. This subgroup was a mean age of 55.9 years (range, 28-69 years), and 60% were men (Table I ). Of the dermatologic conditions, 44% were present on the day of the COVID-19 diagnosis, roughly at the onset of the typical flu-like symptoms. The remaining 56% of dermatoses were observed at a mean of 11.7 days (range, 2-23 days after hospitalization).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
